{"id":"debio-4326","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets mitochondrial NADH dehydrogenase (complex I), impairing ATP production and triggering metabolic stress in tumor cells. This mechanism is particularly relevant in cancers with high metabolic demands or specific mitochondrial dependencies. The selective targeting aims to exploit metabolic vulnerabilities in malignant cells while minimizing effects on normal tissues.","oneSentence":"Debio 4326 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:53.278Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06129539","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Debiopharm International SA","startDate":"2024-07-31","conditions":"Central Precocious Puberty","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Debio 4326","genericName":"Debio 4326","companyName":"Debiopharm International SA","companyId":"debiopharm-international-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Debio 4326 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells. Used for Advanced solid tumors (phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}